AI-Powered Pathology Analysis System Market – By Component, By Technology, By Deployment Mode, By Use Case, By End Use – Global Forecast, 2025 – 2034

AI-Powered Pathology Analysis System Market Size

The global AI-powered pathology analysis system market was estimated at USD 107.5 million in 2024. The market is expected to grow from USD 126.2 million in 2025 to USD 527.8 million in 2034, at a CAGR of 17.2% during the forecast period, according to the latest report published by Global Market Insights Inc.

The AI-powered pathology analysis system market is driven by growing adoption of digital pathology and telepathology, increasing demand for faster diagnostic turnaround time with improved accuracy, rising prevalence of chronic diseases, and advancements in AI algorithms, among other factors.
 

Shortage of skilled pathologists driving demand for automation, integration of AI with genomic and multi-omics data, and strategic collaborations between AI startups and healthcare providers are among the key factors propelling market growth. Quest Diagnostics (PathAI), TEMPUS, IBEX, PROSCIA, and aiforia are among the leading players operating in the market. These players mainly focus on innovation, integration with multiple platforms, geographic expansion, and collaboration with local or regional players.
 

With the consistent growing global burden of chronic illnesses, specifically cancer, cardiovascular conditions, and diabetes, there is an increasing need for better, scalable, and affordable diagnostics. For instance, according to the data reported in a report published by the WHO’s cancer agency, the International Agency for Research on Cancer (IARC), there were more than 20 million new cancer cases recorded in 2022. Conventional methods of pathology often lack the ability to maintain the pace at which volume of work and depth of analysis are required. AI-based systems provide automated image analysis, pattern recognition, and predictive analytics that help pathologists identify disease earlier and with higher specificity. All such developments promote healthcare providers and research organizations to work on implementing AI solutions to achieve better outcomes and reduce time to diagnosis.
 

Additionally, healthcare systems are facing increased pressure to provide timely and accurate diagnoses, especially in oncology and infectious disease cases. With the implementation of AI-enabled pathology-based systems, there is a significant reduction in the time required to analyze tissue for pathological diagnosis by automating image interpretation and abnormality detection. For instance, in July 2025, PathAI, launched its AISight Image Management System (IMS), a first-of-its-kind network of digital anatomic pathology laboratories that enable early access to the latest AI-powered pathology solutions.
 

Further, digital pathology is changing the service delivery system by allowing remote access to high-resolution digital slide images and facilitating collaboration across different geographic locations. Telepathology enables specialists to consult remotely on cases, thus helping to manage the lack of pathologists in rural and underserved areas. Additionally, digital pathology platforms can support AI tools that enrich image analysis, support diagnostic decision-making, and allow for real-time quality control before expert diagnosis.
 

An AI-powered pathology analysis system is a diagnostic platform that uses artificial intelligence to analyze medical images, detect patterns, and assist pathologists in identifying diseases with greater speed, accuracy, and consistency across clinical workflows.
 

AI-Powered Pathology Analysis System Market Trends

Rising demand for precision medicine, digital transformation in pathology, government initiatives and funding for AI in healthcare, and integration of AI-powered analysis tools in the drug development process are among the key trends shaping the industry's growth.
 

• AI-based pathology assists with personalized treatment by linking histopathological data with genomic and clinical information. This shift is driving use in the oncology domain as AI helps with biomarker identification, identifies subtypes of patients for targeted therapies, and diagnostic prediction of treatment response, among other parameters that make diagnostics more actionable.
   
• In addition, the transition from conventional slide-based pathology to digital workflows is gaining momentum. Whole-slide imaging and cloud platforms facilitate remote access, faster analysis, and integration with AI tools. This transition improves diagnostic efficiency, especially for telepathology in rural and underserved areas.
   
• Further, pharmaceutical companies are utilizing AI pathology tools to analyze human tissue samples in clinical trials, including monitoring for treatment effects and biomarker validation, which shortens drug discovery timelines and increases trial efficiencies. The integration of AI in pathology results in a commercial incentive and maximizes return on clinical research investment.
   

AI-Powered Pathology Analysis System Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2021, the market was valued at USD 51.2 million and grew to USD 67.5 million in 2022, reaching USD 87.3 million by 2023. AI integration in cancer screening and early detection programs, and demand for faster diagnostic turnaround times are among the key variables contributing to industry growth.
 

Based on component, the global AI-powered pathology analysis system market is segmented into software, hardware, and services. The software segment accounted for a leading share of 52.7% in 2024. Adoption of AI tools in drug discovery and clinical trials is anticipated to fuel the segmental growth. The segment is expected to exceed USD 286.9 million by 2034, growing at a CAGR of 17.6% during the forecast period.
 

• There is a growing demand for software solutions because of their importance in software-enabled artificial intelligence apps. For example, image analysis, pattern recognition, and diagnostic decision support systems are all applications that require software solutions.
   
• Additionally, the number of hospitals and labs adopting software solutions is consistently growing as platforms that automate workflow processes while integrating with electronic health records (EHR) systems are widely accepted as a solution for labs or hospitals.
   
• Predictive analytics tools are desirable as they can be used to drive early disease detection and treatment management. As the advancement of AI models progresses, so does the demand for software solutions that are scalable, interoperable, and cloud based.
   
• The hardware segment was valued at USD 32.5 million in 2024. The demand for hardware is largely fueled by the need for imaging and data acquisition systems with high resolution and AI analysis capabilities. Whole-slide imaging (WSI) scanners and digital pathology systems are tools required for the transition from physical slides to digital, and they can be used for AI image processing as well.
   
• In addition, microscopes with imaging capabilities and storage space that can accommodate the pathology data have a key importance.
   
• Further, as organizations switch to digital workflows, hardware infrastructure investment is witnessing a surge, especially in larger hospitals and research centers.
   
• Moreover, the services segment is expected to record robust growth with a CAGR of 16.5% through the analysis timeframe. There is a growing demand for health systems that need assistance with the implementation and maintenance of AI pathology systems.
   
• Various labs, hospitals, and other healthcare providers face difficulties in adopting and implementing AI tools and solutions, which is propelling the demand for consulting services, training, and managed services.
   
• Furthermore, as the use of AI tools expands, service providers have also started offering data annotation, validation of models, and regulatory compliance services. The services segment plays an important role in the successful deployment and use of AI tools among organizations with limited resources.
   

Based on technology, the global AI-powered pathology analysis system market is segmented into machine learning (ML), computer vision-based image analysis, and natural language processing (NLP). The machine learning segment accounted for a leading share and was valued at USD 45.2 million in 2024.
 

• Machine learning serves as the mainstay of AI pathology systems, as its capabilities to learn from large datasets and enhance accuracy over time create significant demand. Algorithms such as convolutional neural networks (CNNs) and generative adversarial networks (GANs) are prevalent because of their efficacy in identifying complicated patterns in histopathological images, enabling early detection of diseases such as cancer.
   
• Additionally, machine learning (ML) models are increasingly trained on diverse datasets to mitigate biases and improve generalization in terms of different populations.
   
• Further, as healthcare providers need scalable and adaptive diagnostic tools, ML-based systems are necessary for automating workflows, supporting clinical decision making, and facilitating research in pathology.
   
• The computer vision-based image analysis segment was valued at USD 37.4 million in 2024. Computer vision is at the forefront of AI pathology, allowing for the automated reading of high-resolution digital slide images. Its adoption is growing as it allows rapid and consistent reading of cellular abnormalities, tissue segmentation, and quantification of biomarkers.
   
• In addition, computer vision technologies are being incorporated into digital pathology platforms for remote consultations and real-time evaluations. As imaging capabilities improve and numbers of imaging datasets continue to grow, the ability to deliver accurate, reliable, and actionable information using computer vision continues to grow, especially in the areas of cancer screening and chronic disease monitoring.
   
• The NLP category is expected to record substantial growth with a CAGR of 16.9% over the forecast period. The use of NLP in pathology is on the rise due to its ability to extract and interpret unstructured clinical data such as pathological reports and patient histories. Growing demand for NLP tools allows correlation between textual findings and image-based diagnostic findings, helping in context-based decision-making.
   
• The automation of report generation, flagging inconsistencies, and supporting clinical documentation are other areas of interest for these systems.
   
• Moreover, as interoperability and integrating data become the priority of pathology, NLP is expected to position itself as a key enabler in creating a holistic, comprehensive, AI-driven ecosystem.
   

Based on deployment mode, the AI-powered pathology analysis system market is segmented into cloud, and on-premise. The cloud segment accounted for the leading market share of 62.5% in 2024 as it offers real-time updates and enhanced integration.
 

• There is an increasing demand for AI pathology systems hosted on the cloud due to their scalability, flexibility, and affordability. Cloud platforms provide healthcare providers with remote access for using different AI-based diagnostic tools, and improvements in collaboration are enabled across institutions and geographies.
   
• Cloud-based solutions allow for real-time updates to devices and centralized data storage and can integrate with other digital health systems. Cloud services provide faster AI model training and deployment, particularly for large datasets.
   
• Additionally, hospitals and laboratories prefer to use cloud-based solutions to reduce costs associated with developing and maintaining an infrastructure while also providing easier access to digital health interventions.
   
• On-premise segment was valued at USD 40.3 million in 2024. On-premise deployment is a preferred choice for organizations emphasizing data security, regulatory compliance, and control over the infrastructure.
   
• Further, institutions such as hospitals and labs with confidential patient data prefer on-premise servers for privacy and strict governance purposes. In addition, an on-premise deployment allows for easy customization and integration with traditional equipment, which is particularly important for organizations that have already built their workflows around these datasets.
   

Based on use case, the global AI-powered pathology analysis system market is segmented into drug discovery, disease diagnosis & prognosis, clinical workflow, and training & education. The drug discovery segment accounted for a leading share and was valued at USD 43.5 million in 2024.
 

• AI-driven pathology systems are becoming more common in the drug discovery process to evaluate tissue samples, identify biomarkers, and track treatment effects. This is a prominent area of interest as pharmaceutical companies are looking for quicker, more accurate methods to validate drug efficacy and safety throughout the preclinical and clinical development process.
   
• Pathology systems are beneficial in automating histological analyses, minimizing manual errors, and streamlining decision-making processes.
   
• Furthermore, AI-based pathology systems allow for assessments of pathology data alongside genomic and molecular profiling to facilitate targeted therapies and personalized medicine.
   
• Finally, the expansion of drug pipelines highlights the need to assess pathology analysis in a scalable and reproducible manner, driving uptake in this area.
   
• The disease diagnosis & prognosis segment is anticipated to record robust growth with a CAGR of 17.3% over the forecast timeline. This represents one of the major use cases, supporting growing demand for early and accurate disease detection. AI systems support pathologists with the detection of subtle morphological changes in tissues, which improves diagnostic precision and lowers turnaround time. They also help with prognostic assessments by identifying patterns related to disease and treatment outcomes.
   
• Hospitals and diagnostic laboratories are adopting these tools to improve screening for cancer, detection of infectious disease, and monitoring of chronic conditions.
   
• Moreover, the clinical workflow segment held substantial share in 2024. The popularity of AI-driven pathology tools for clinical workflows is growing as healthcare organizations try to enhance workflows and decrease diagnostic bottlenecks. These technologies may take over high-volume, low-skilled tasks that involve screening slides, identifying abnormalities, and generating reports, thereby enabling pathologists to focus on other complex issues.
   
• As hospitals seek to improve efficiency to decrease time to diagnosis, while maintaining diagnostic quality with increased volume, AI is anticipated to become more critical in the workflow of modern pathology.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the AI-powered pathology analysis system market is segmented into hospitals & diagnostic laboratories, life sciences companies, research institutes & academic centers, and other end users. The hospitals & diagnostic laboratories segment accounted for the leading market share of 38.6% in 2024 as it records high patient footfall including both public and private hospital settings.
 

• Hospitals and diagnostic laboratories are the leading end users of AI-based pathology systems primarily as a result of the high need for accurate and timely diagnostic services capable of high-throughput analysis.
• Demand stems from the pressure to improve diagnostic consistency, reduce turnaround time, and manage increasing volume with limited pathology staffing. AI-based tools are utilized to analyze slides, flag abnormal findings, and assist in clinical decision-making, particularly in oncology and infectious disease cases.
   
• Additionally, the integration of AI systems with electronic medical records and hospital information systems provides an efficiency of workflow. As healthcare organizations move towards modernization of their infrastructure, AI implementation is becoming a central component to improving patient outcomes and operational efficiencies in the healthcare environment.
   
• The life sciences companies segment was valued at USD 39 million in 2024. Life science firms utilize AI pathology systems to improve drug discovery, gain insights into biomarkers, and analyze clinical trials. There is an increased need for AI pathology systems as life science organizations seek scalable and reproducible workflows to analyze tissue samples and validate therapeutic targets. Additionally, AI allows for the analysis of tissue samples to occur at high throughput, which improves efficiency and accuracy while reducing the burden of manual image review. AI also provides reproducible, standardized, and traceable results to enable regulatory submission.
   
• Further, with the increased focus on precision medicine and targeted therapies, life sciences firms prefer to invest in AI-based systems to augment research productivity and reduce time to market.
   

Looking for region specific data?

Download Free PDF

North America AI-Powered Pathology Analysis System Market

North America AI-powered pathology analysis system market accounted for majority share of 47.7% in 2024 in the global market and is anticipated to show notable growth over the forecast period.

• North America dominates the global market, supported by the presence of strong healthcare infrastructure, high digital pathology adoption rates, and a proven track record of significant investment in AI research. For example, as per the recently published data, out of the total 194 digital pathology platform startups, 81 are based in North America, with 69 in the U.S. and 12 in Canada.
   
• AI companies in the U.S., such as PathAI, Proscia, and Tempus, have emerged as key innovators by collaborating with hospitals and pharmaceutical companies. AI tools are commonly used in cancer diagnostics, biomarker development, and clinical trials. Regulatory clarity and integration with electronic health records support widespread deployment.
   
• In addition, there is increasing use of cloud-based platforms and telepathology to support access and collaboration. Increasing reliance on precision medicine and chronic disease interventions continues to further drive growth in this market.
   

The U.S. AI-powered pathology analysis system market was valued at USD 23.1 million and USD 30.5 million in 2021 and 2022, respectively. In 2024 the market size was valued at USD 48.2 million from USD 39.3 million in 2023. As research becomes increasingly data-driven, AI systems are essential for enabling innovation and fostering growth in the country.
 

• The U.S. is the leading contributor in North America, primarily due to increased uptake of digital technology and significant research and development funding. Hospitals and diagnostic laboratories are quickly adopting AI to drive faster and more accurate diagnoses.
   
• Tempus and Aiforia are two companies expanding through strategic acquisitions and partnerships. For instance, in August 2025, Tempus announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in the digital pathology industry. AI tools are simultaneously being incorporated in oncology, pathology automation, and personalized medicine specifically.
   
• Moreover, the U.S. has the advantage of a solid regulatory structure and reimbursement models to support the use of digital diagnostics.
   
• Further, cloud-native platforms and AI-powered image analysis are beginning to represent standard approaches in clinical workflows, particularly at cancer centers and academic institutions.
   

Europe AI-Powered Pathology Analysis System Market

Europe accounted for a substantial share in the market and was valued at USD 31.4 million in 2024.
 

• There is substantial adoption of AI pathology in Europe due to the digitization of healthcare and regulatory efforts. Strong leaders in this deployment include Germany, France, and the UK, which focus on personalized medicine and telepathology.
   
• AI tools are implemented for biomarker discovery, disease classifications, and remote consultation. Integration with EHRs and standards for interoperability have improved workflow efficiency.
   
• Additionally, AI educational programs and collaborative platforms are also gaining traction, particularly in addressing pathologist shortages. In addition, there continues to be an intent to provide regulatory clarity around AI and to ensure ethical deployment of AI tools in the context of building trust towards adoption across hospitals and research institutes.
   

Germany held significant share of the European AI-powered pathology analysis system market, showcasing strong growth potential.
 

• Germany leads the European market for AI pathology as a result of high cancer rates and the need for more efficient diagnostic approaches. Germany-based hospitals and laboratories are increasingly deploying digital pathology systems for remote analysis and AI-assisted interpretation.
   
• In addition, companies such as Elea and MindPeak are driving innovation in AI operating systems and diagnostic tools. The country is also investing significant resources in the modernization of the healthcare infrastructure and AI integration throughout various departments.
   
• Further, partnerships between technology firms and hospital networks support these implementations, and Germany's focus on precision diagnostics and clinical trials is resulting in strong demand for scalable and interoperable AI pathology platforms.
   

Asia Pacific AI-Powered Pathology Analysis System Market

The Asia Pacific AI-powered pathology analysis system market accounted for a significant share in the market and was valued at USD 19.5 million in 2024.
 

• Asia Pacific's rapid expansion stems from increasing healthcare investments, growing governmental AI initiatives, and the availability of a large target population for different disorders. China, India, and Japan have driven faster adoption in their respective countries through hospital digitization and cancer screening programs.
   
• AI tools are being used across disease diagnosis, academic research, and drug discovery. Both local startups and global life science firms are engaging to implement AI pathology solutions in areas of need. Surging demand for precision medicine, affordable diagnosis, and telepathology services is driving the regional growth cycle.
   
• The region also benefits from favorable reforms that are key to the regulatory environment and increased insurance coverage, particularly beneficial in facilitating access to AI pathology throughout the region.
   

China AI-powered pathology analysis system market is estimated to grow with a robust CAGR, in the Asia Pacific market.
 

• China's AI pathology sector is growing rapidly, fueled by increasing rates of cancer incidence, a shortage of pathologists in the healthcare system, and robust government support of AI-related tools. Hospitals and research institutions utilize whole slide imaging and AI-based pathology tools to enhance the speed of diagnosis and enable remote consultations.
   
• Regulatory authorities are validating AI-based systems for clinical applications in pathology, advancing clinician confidence and expanding their use.
   
• Additionally, the use of cloud-based platforms and the integration with laboratory information management systems (LIMS) are improving workflow efficiency.
   
• Various commercial organizations are also employing AI applications in pathology for biomarker quantification, abnormality detection, and predictive analytics. National screening programs, alongside upgrades of digital health infrastructure, are contributing to accelerated growth of the market.
   

Latin America AI-Powered Pathology Analysis System Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is emerging as a key market in Latin America, driven by rising demand for diagnostic accuracy and healthcare modernization. Institutions such as Rede D’Or are pioneering large-scale AI pathology deployment.
• Remote pathology tools and teleconsultation services are addressing specialist shortages in underserved regions. Regulatory approvals and cloud-based platforms are enhancing adoption.
   
• In addition, AI is being used for cancer screening, research, and clinical trials. Investments in infrastructure and training programs are supporting market expansion.
   
• Further, Brazil’s focus on decentralizing diagnostics and improving access is creating strong demand for scalable AI pathology solutions.
   

Middle East and Africa AI-Powered Pathology Analysis System Market

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia is rapidly adopting AI-powered pathology systems as part of its healthcare digitization strategy. Hospitals and labs are integrating whole-slide imaging and AI tools to improve diagnostic speed and accuracy.
• Government initiatives and regulatory approvals are fostering trust and investment. Telepathology is expanding access in remote regions, while cloud platforms support collaboration and scalability.
   
• Moreover, AI is being used for oncology diagnostics, research, and national screening programs. Challenges such as infrastructure costs and workflow resistance are being addressed through training and phased rollouts. The market is poised for strong growth as digital transformation accelerates.
   

AI-Powered Pathology Analysis System Market Share

The competitive landscape within the AI-powered pathology analysis systems market is witnessing dynamic changes based on innovation, partnerships, and increasing demand for precision diagnostics. Leading companies such as PathAI (with Quest Diagnostics), Tempus, Ibex Medical Analytics, Proscia, and Aiforia have a considerable presence in the market through differentiated approaches by respective players. These top 5 players are contributing 42% of market share.
 

PathAI is focused on embedding AI into clinical workflows and scaling in digital pathology through partnerships. Tempus is applying multimodal data and generative AI to develop oncology models after a recent acquisition. Ibex emphasizes clinical validation, and real-time diagnostics support while collaborating with healthcare providers for global expansion. Similarly, Proscia is improving enterprise-grade digital pathology platforms for labs implementing AI at scale and enable commercialization of their data.
 

Further, the competitive landscape is characterized by a mix of innovative startups and established healthcare firms, with competition focused on algorithm accuracy, regulatory approvals, scalability of the platform, and integration capabilities. As companies adopt AI-based systems, the key players are improving their presence through interoperability, cloud-based, and clinically validated solutions. Moreover, partnerships and acquisitions are anticipated to further consolidate the market landscape, especially in oncology and drug development.
 

AI-Powered Pathology Analysis System Market Companies

Few of the prominent players operating in the global AI-powered pathology analysis system industry include:

• aetherAI
• aiforia
• Aiosyn
• deep bio
• HOLOGIC
• IBEX
• indica labs
• KFBIO
• mindpeak
• PHILIPS
• PROSCIA
• QRITIVE
• Quest Diagnostics (PathAI)
• Roche
• TEMPUS
• tribun HEALTH
• VISIOPHARM
   
• Quest Diagnostics (PathAI)

PathAI accounted for the leading share in the market with around 12% in 2024. Quest is integrating PathAI’s AI pathology lab and algorithms to enhance cancer diagnostics. Their strategy focuses on scaling digital pathology, licensing AI tools, and leveraging Quest’s oncology expertise to improve diagnostic speed, quality, and accessibility.
 

• TEMPUS

Tempus acquired Paige to expand its digital pathology capabilities, aiming to build the largest oncology foundation model. Their strategy centers on multimodal data integration, generative AI, and precision medicine to accelerate cancer detection and drug development.
 

• IBEX

Ibex focuses on deploying clinically validated AI tools for cancer diagnostics, partnering with Philips and Roche to integrate AI into pathological workflows. Their strategy emphasizes global expansion, real-time quality control, and enhancing diagnostic accuracy across tissue types.
 

AI-Powered Pathology Analysis System Industry News:

• In July 2025, Mindpeak announced its new collaboration with Techcyte, a key provider of AI-driven digital diagnostics, by joining the Techcyte Fusion Partner Program. This partnership enables both the companies offering their solutions in AI for pathology, to enhance their diagnostic accuracy, efficiency, and reproducibility in cancer research and diagnostics.
   
• In March 2025, Philips announced the expansion of its partnership with Ibex Medical Analytics (Ibex) and a new release of Philips IntelliSite Pathology Solution (PIPS) to further accelerate the adoption of AI-enabled digital pathology solutions. This partnership is expected to enhance AI-enabled pathology workflows for better patient care through interoperable AI-powered digital pathology offerings.
   
• In November 2024, Deep Bio, a key player in artificial intelligence for digital pathology, announced a collaboration to integrate its prostate cancer analysis solution, DeepDx Prostate, with PathAI’s AISight1 Image Management System (IMS). This collaboration combines Deep Bio’s clinically validated AI technology with PathAI’s advanced digital pathology platform, expanding access to powerful diagnostic tools for prostate cancer.
   

The global AI-powered pathology analysis system market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Software
  • Image analysis & pattern recognition                
  • Predictive analytics tools              
  • Workflow automation software               
  • Diagnostic decision support          
• Hardware
  • Whole slide imaging (WSI) scanners                 
  • Digital pathology systems            
  • Microscopes            
  • Storage systems               
• Services
  • Implementation & integration                 
  • Consulting & training                   
  • Managed AI services          
  • Maintenance & support      

Market, By Technology

• Machine Learning (ML)                                    
  • Convolutional neural networks (CNNS)             
  • Generative adversarial networks (GANS)           
  • Recurrent neural networks (RNNS)         
  • Other neural networks                 
• Computer vision-based image analysis
• Natural language processing (NLP)

Market, By Deployment Mode

• Cloud
• On-premise

Market, By Use Case

• Drug discovery
• Disease diagnosis & prognosis
• Clinical workflow
• Training & education

Market, By End Use

• Hospitals & diagnostic laboratories
• Life sciences companies
• Research institutes & academic centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE